This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by TAUBER, J. P. Articles by BAYARD, F. Search for Related Content PubMed PubMed Citation Articles by TAUBER, J. P. Articles by BAYARD, F.

Long Term Effects of Continuous Subcutaneous Infusion of the Somatostatin Analog Octreotide in the Treatment of Acromegaly

Departments of Endocrinology, Neuroradiology (A.B.), and Pediatrics (M.T.T., F.V.) CHR Rangueil, Chemin du Vallon, Cedex F-31054 Toulouse, France
the Department of Neuroendocrinology, Sandoz Ltd., Clinical Research (A.G.H.) CH-4002 Basel, Switzerland

Address all correspondence and requests for reprints to: J. P. Tauber, Department of Endocrinology, CHR Rangueil, Chemin du Vallon, Cedex F-31054 Toulouse, France.

The marked pituitary tumor shrinkage achieved by continuous sc infusion (CSI) of the long-acting somatostatin analog octreotide in one acromegalic patient led us to treat 16 other acromegalic patients for up to 24 months by CSI. This therapy, given in doses ranging from 100–600 µg/day, resulted in normalization of the mean daily serum GH (mGH) and insulin-like growth factor I levels in 9 of the 17 patients (53%). In 7 patients, mean daily serum GH decreased but not to normal; 3 of these patients had hyperprolactinemia which was not influenced by octreotide. One patient was completely unresponsive. In contrast to the biochemical results, 80% of the patients had marked clinical improvement. Side-effects consisted of slightly impaired carbohydrate tolerance in 2 patients and cholelithiasis in 2 patients. Pituitary tumor size decreased in only 3 patients; in 1 of them visual field defects disappeared rapidly. These results suggest that octreotide treatment may prove beneficial before surgery in patients with macroadenomas, although its efficacy varies widely. Potential responsivity can usually be determined by a short course (24 h) of CSI of octreotide.

Received August 15, 1988.

This article has been cited by other articles:

				A. Pokrajac, J. Frystyk, A. Flyvbjerg, and P. J Trainer Pituitary-independent effect of octreotide on IGF1 generation Eur. J. Endocrinol., April 1, 2009; 160(4): 543 - 548. [Abstract] [Full Text] [PDF]

				G M Besser, P Burman, and A F Daly Predictors and rates of treatment-resistant tumor growth in acromegaly Eur. J. Endocrinol., August 1, 2005; 153(2): 187 - 193. [Abstract] [Full Text] [PDF]

				P. U. Freda, L. Katznelson, A. J. van der Lely, C. M. Reyes, S. Zhao, and D. Rabinowitz Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analysis J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4465 - 4473. [Abstract] [Full Text] [PDF]

				J. Ayuk, S. E. Stewart, P. M. Stewart, and M. C. Sheppard Long-Term Safety and Efficacy of Depot Long-Acting Somatostatin Analogs for the Treatment of Acromegaly J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4142 - 4146. [Abstract] [Full Text] [PDF]

				J. Zapf, M. Gosteli-Peter, G. Weckbecker, E. B. Hunziker, and M. Reinecke The Somatostatin Analog Octreotide Inhibits GH-Stimulated, But Not IGF-I-Stimulated, Bone Growth in Hypophysectomized Rats Endocrinology, August 1, 2002; 143(8): 2944 - 2952. [Abstract] [Full Text] [PDF]

				P. U. Freda and S. L. Wardlaw Diagnosis and Treatment of Pituitary Tumors J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3859 - 3866. [Full Text]

				M. R. Drange and S. Melmed Long-Acting Lanreotide Induces Clinical and Biochemical Remission of Acromegaly Caused by Disseminated Growth Hormone-Releasing Hormone-Secreting Carcinoid J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3104 - 3109. [Abstract] [Full Text]

				S. Melmed, I. Jackson, D. Kleinberg, and A. Klibanski Current Treatment Guidelines for Acromegaly J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2646 - 2652. [Abstract] [Full Text]

				P. Caron, L. Buscail, A. Beckers, J.-P. Esteve, A. Igout, G. Hennen, and C. Susini Expression of Somatostatin Receptor SST4 in Human Placenta and Absence of Octreotide Effect on Human Placental Growth Hormone Concentration during Pregnancy J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3771 - 3776. [Abstract] [Full Text] [PDF]

				A. K. Flogstad, J. Halse, S. Bakke, I. Lancranjan, P. Marbach, Ch. Bruns, and J. Jervell Sandostatin LAR in Acromegalic Patients: Long Term Treatment J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 23 - 28. [Abstract] [Full Text] [PDF]

				M. L. Vance and A. G. Harris Long-term Treatment of 189 Acromegalic Patients With the Somatostatin Analog Octreotide: Results of the International Multicenter Acromegaly Study Group Arch Intern Med, August 1, 1991; 151(8): 1573 - 1578. [Abstract] [PDF]

				W. H. Daughaday Octreotide Is Effective in Acromegaly But Often Results in Cholelithiasis Ann Intern Med, February 1, 1990; 112(3): 159 - 160. [Abstract] [PDF]